Gamida Cell Ltd. (GMDA)

Market Cap	110.38M
Revenue (ttm)	n/a
Net Income (ttm)	-87.41M
Shares Out	74.58M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,136,408
Open	1.36
Previous Close	1.32
Day's Range	1.33 - 1.53
52-Week Range	1.10 - 4.72
Beta	1.66
Analysts	Buy
Price Target	12.65 (+754.73%)
Earnings Date	Mar 27, 2023

About GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Ho...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 26, 2018
• Employees: 166
• Stock Exchange: NASDAQ
• Ticker Symbol: GMDA

Analyst Forecast

According to 11 analysts, the average rating for GMDA stock is "Buy." The 12-month stock price forecast is $12.65, which is an increase of 754.73% from the latest price.

Price Target

$12.65

(754.73% upside)

Analyst Consensus: Buy